79 related articles for article (PubMed ID: 37481795)
21. Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.
Chiu JWY; Lee SC; Ho JC; Park YH; Chao TC; Kim SB; Lim E; Lin CH; Loi S; Low SY; Teo LLS; Yeo W; Dent R
Drug Saf; 2023 Oct; 46(10):927-949. PubMed ID: 37552439
[TBL] [Abstract][Full Text] [Related]
22. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N
Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454
[TBL] [Abstract][Full Text] [Related]
23. HER2-low metastases of HER2-negative primary tumors: a single institution analysis of intertumoral and internodal heterogeneity in node-positive breast cancer.
Pellas U; Bauer A; Baroš IV; Fattorini C; Tot T
Front Oncol; 2023; 13():1167567. PubMed ID: 37483511
[TBL] [Abstract][Full Text] [Related]
24. Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis.
Soares LR; Vilbert M; Rosa VDL; Oliveira JL; Deus MM; Freitas-Junior R
ESMO Open; 2023 Aug; 8(4):101613. PubMed ID: 37481956
[TBL] [Abstract][Full Text] [Related]
25. A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer.
Hashimoto T; Takayanagi D; Yonemaru J; Naka T; Nagashima K; Machida E; Kohno T; Yatabe Y; Kanemitsu Y; Hamamoto R; Takashima A; Shiraishi K; Sekine S
Br J Cancer; 2023 Oct; 129(7):1176-1183. PubMed ID: 37543670
[TBL] [Abstract][Full Text] [Related]
26. Circulating microRNAs can predict chemotherapy-induced toxicities in patients being treated for primary breast cancer.
Davey MG; Abbas R; Kerin EP; Casey MC; McGuire A; Waldron RM; Heneghan HM; Newell J; McDermott AM; Keane MM; Lowery AJ; Miller N; Kerin MJ
Breast Cancer Res Treat; 2023 Nov; 202(1):73-81. PubMed ID: 37540289
[TBL] [Abstract][Full Text] [Related]
27. Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape.
Lekshmy M; Dhanya CR; Smrithi JS; Sindhurani JA; Vandanamthadathil JJ; Veettil JT; Anila L; Lathakumari VS; Nayar AM; Madhavan M
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513965
[TBL] [Abstract][Full Text] [Related]
28. Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
Gaynor N; Blanco A; Madden SF; Moran B; Fletcher JM; Kaukonen D; Ramírez JS; Eustace AJ; McDermott MSJ; Canonici A; Toomey S; Teiserskiene A; Hennessy BT; O'Donovan N; Crown J; Collins DM
Br J Cancer; 2023 Oct; 129(6):1022-1031. PubMed ID: 37507543
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic resistance to anti-oestrogen therapy in breast cancer.
Will M; Liang J; Metcalfe C; Chandarlapaty S
Nat Rev Cancer; 2023 Oct; 23(10):673-685. PubMed ID: 37500767
[TBL] [Abstract][Full Text] [Related]
30. Direct and indirect effects of COVID-19 on short-term mortality of breast cancer patients.
Di Cosimo S; Ljevar S; Trama A; Bernasconi A; Lasalvia P; De Santis MC; Cappelletti V; Miceli R; Apolone G
Breast; 2023 Oct; 71():60-62. PubMed ID: 37499377
[TBL] [Abstract][Full Text] [Related]
31. Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis.
Matsui C; Shibata N; Hirai C; Tada M; Kikawa Y; Sugie T
Case Rep Oncol; 2023; 16(1):491-496. PubMed ID: 37497420
[TBL] [Abstract][Full Text] [Related]
32. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC; Howell S; Lord SR; Kenny L; Mansi J; Mitri Z; Palmieri C; Chap LI; Richards P; Gradishar W; Sardesai S; Melear J; O'Shaughnessy J; Ward P; Chalasani P; Arkenau T; Baird RD; Jeselsohn R; Ali S; Clack G; Bahl A; McIntosh S; Krebs MG
Nat Commun; 2023 Jul; 14(1):4444. PubMed ID: 37488191
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report.
Fan S; He L; Sang D
Oncol Lett; 2023 Aug; 26(2):359. PubMed ID: 37545624
[TBL] [Abstract][Full Text] [Related]
34. Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations.
Moser SS; Mazursky OF; Shalev H; Apter L; Chodick G; Siegelmann-Danieli N
Future Oncol; 2023 Jul; 19(21):1473-1483. PubMed ID: 37529919
[TBL] [Abstract][Full Text] [Related]
35. Multiparametric MRI and Radiomics for the Prediction of HER2-Zero, -Low, and -Positive Breast Cancers.
Ramtohul T; Djerroudi L; Lissavalid E; Nhy C; Redon L; Ikni L; Djelouah M; Journo G; Menet E; Cabel L; Malhaire C; Tardivon A
Radiology; 2023 Aug; 308(2):e222646. PubMed ID: 37526540
[TBL] [Abstract][Full Text] [Related]
36. Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).
Masuyama M; Masuda N; Kawaguchi H; Yamamoto Y; Saji S; Nakayama T; Aogi K; Anan K; Ohtani S; Sato N; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita T; Yotsumoto D; Toi M; Ohno S
Cancer Med; 2023 Sep; 12(17):17718-17730. PubMed ID: 37525895
[TBL] [Abstract][Full Text] [Related]
37. Characterization and spatial distribution of the immune cell infiltrate in triple-negative breast cancer: a novel classification based on plasma cells and CD8+ T cells.
Gonzàlez-Farré M; Gibert J; Santiago-Díaz P; Menéndez S; Monzonis X; Olivares F; Riera X; López D; Torner A; Casado B; Bellosillo B; Lloveras B; Casadevall D; Rovira A; Servitja S; Albanell J; Vázquez I; Comerma L
Hum Pathol; 2023 Sep; 139():91-105. PubMed ID: 37517596
[TBL] [Abstract][Full Text] [Related]
38. Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects.
Nordin ML; Azemi AK; Nordin AH; Nabgan W; Ng PY; Yusoff K; Abu N; Lim KP; Zakaria ZA; Ismail N; Azmi F
Pharmaceuticals (Basel); 2023 Jun; 16(7):. PubMed ID: 37513835
[TBL] [Abstract][Full Text] [Related]
39. Calcium-Sensing Receptor Expression in Breast Cancer.
Busic-Pavlek I; Dumic-Cule I; Kovacevic L; Milosevic M; Delimar P; Korsa L; Marusic Z; Prutki M
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511437
[TBL] [Abstract][Full Text] [Related]
40. An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer.
Cheng SX; Chen QC; Lin GH; Han YH; Wang BC; Dai Y; Zhao YX
Medicine (Baltimore); 2023 Jul; 102(30):e34486. PubMed ID: 37505137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
